Numerous DNA damaging CRC therapies including doxorubicin and oxaliplatin, drive cell stress, inducing p53-mediated transcription of genes activating processes such as cell cycle arrest, senescence, and apoptosis. Here, TP53 is linked to colorectal carcinoma.